NHS faces legal challenge from Novartis over use of intravitreal bevacizumab (AvastinT) for wet AMD

Source: BBC Health
Area: News
The BBC has reported that Novartis is challenging the NHS on the use of intravitreal bevacizumab (AvastinT) instead of the NICE-recommended ranibizumab (LucentisT) for the treatment of wet age-related macular degeneration (AMD).   Both drugs are manufactured by Novartis but bevacizumab is not licensed for this indication and has been widely used off-label because it is a cheaper alternative. Ranibizumab costs around £740 per injection, and has been specifically developed for use in ocular conditions with a supporting European licence and safety approval for treating (Read more...)

Full Story →